Health Condition 1: D898- Other specified disorders involving the immune mechanism, not elsewhere classified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The Patients must meet ALL the following criteria: 1. Male or female subjects with 18 years and above of age 2. Subjects must be willing to participate in the study and provide a written informed consent 3. Patient diagnosed with gram positive bacterial infection in Immunocompromised condition including but not limited to Immunodeficiency and immunosuppressive drug therapy by International Classification of Disease (ICD-10 version 2019) to be treated with Levonadifloxacin (IV or Oral) as per investigatorâ??s discretion.
Exclusion criteria
Exclusion criteria: The Patients must not meet any the following criteria: 1. Subjects with history of hypersensitivity to any of the study drugs or same class of drugs 2. Subjects who received any experimental drug within 30 days prior to enrolment 3. Subjects who, in the judgment of the Investigator, are likely to be noncompliant or uncooperative during the study 4. Subjects with any abnormality that the Investigator deems to be clinically relevant, either on medical history, physical examination or ECG
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EfficacyTimepoint: Primary end point : Clinical Response on Day 4, End of Treatment (EOT) and Test of Cure (TOC) Secondary end point : Microbiological Response on End of Treatment (EOT) | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety - Tolerability EndpointTimepoint: Safety evaluation will be based on Adverse Events (AEs) reported, vital signs and physical examination findings, clinical laboratory evaluation, and ECG collected during the study. | — |
Countries
India
Contacts
Wockhardt Limited